Oric Market Share Analysis for May 2026

The ORIC app stimulates your vagus nerve with your favorite music. ORIC is based on insights of the Polyvagal Theory, proposed by Stephen W. Porges. Oric makes you feel safe with sounds and music. Oric is a science based sound app, that enriches any music to improve the physiological stress response and makes you feel safe, just by listening to your favourite sounds with headphones.

Industry: N/A

Domainoric.com

Year Founded--

Employees1001 - 5000

Annual Revenue$2M - $5M

Oric

Oric (including company regionals)

oric.com

See more website traffic and engagement information

Oric Revenue up to May 2026 is 2M - 5M

revenue generated by Oric top domains

Oric top domains revenue over 3 years

Revenue for Oric top domains

oric.com2M - 5M

See more with Sales Intelligence

Total visits to Oric's top domains

Understand Oric market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

oric.com3K

See more with Sales Intelligence

Avg. visit duration in Oric's top domains

Analyze Oric engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Oric's top domains

See how Oric keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

oric.com1.09

See more with Sales Intelligence

Oric top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Oric

These are the website technologies, by industry, used by Oric top domains

Conversion & Analytics (5)

Google Analytics

Payment & Currencies (5)

Cart Functionality

Advertising (1)

PubMatic

Mobile (1)

Apple Mobile Tags

More Technologies

1

See all

News & Signals from Oric

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOric launches lead drug candidate ORIC-101.In its year-end financial report, Oric announced the discontinuation of its lead drug candidate ORIC-101, which was being assessed in several early-stage cancer studies.